Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer

NCT00262847 is registered in ClinicalTrials.gov with National Cancer Institute (NCI) as lead sponsor.

NCT NCT00262847
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00262847 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase III Trial of Carboplatin and Paclitaxel Plus Placebo Versus Carboplatin and Paclitaxel Plus Concurrent Bevacizumab (NSC # 704865) Followed by Placebo, Versus Carboplatin and Paclitaxel Plus Concurrent and Extended Bevacizumab, in Women With Newly Diagnosed, Previously Untreated, Stage III or IV Epithelial Ovarian, Primary Peritoneal or Fallopian Tube Cancer
Lead sponsor
National Cancer Institute (NCI)
Phase
Phase 3
Overall status
Completed
Start date
September 30, 2005
Completion date
April 30, 2015
Enrollment
1,873 (actual)
Sites
632

Conditions

As the registry lists them; a condition with its own page is linked.

fallopian tube clear cell adenocarcinoma, fallopian tube endometrioid adenocarcinoma, fallopian tube mucinous adenocarcinoma, fallopian tube serous adenocarcinoma, fallopian tube transitional cell carcinoma, malignant ovarian mixed epithelial tumor, ovarian brenner tumor, ovarian clear cell adenocarcinoma, ovarian endometrioid adenocarcinoma, ovarian mucinous adenocarcinoma, ovarian serous adenocarcinoma, ovarian transitional cell carcinoma, primary peritoneal serous adenocarcinoma, stage iiia fallopian tube cancer, stage iiia ovarian cancer, stage iiia primary peritoneal cancer, stage iiib fallopian tube cancer, stage iiib ovarian cancer, stage iiib primary peritoneal cancer, stage iiic fallopian tube cancer, stage iiic ovarian cancer, stage iiic primary peritoneal cancer, stage iv fallopian tube cancer, stage iv ovarian cancer, stage iv primary peritoneal cancer, undifferentiated fallopian tube carcinoma, undifferentiated ovarian carcinoma